Insulet (PODD) Return on Capital Employed (2011 - 2026)
Insulet (PODD) posted Return on Capital Employed of 21.12% for Q1 2026, up 8.29% on a QoQ basis from 19.5% in Q4 2025, and up 888.0% year-over-year from 2.14% in Q1 2025.
Insulet (PODD) Return on Capital Employed (2011 - 2026) Analysis & Trends
Insulet's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 21.12% for Q1 2026.
- Quarterly Return on Capital Employed rose 888.0% year-over-year to 21.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.12% (up 888.0% YoY) and the FY2025 annual result came in at 19.27%, up 589.0% from the prior year.
- Return on Capital Employed was 21.12% for Q1 2026 at Insulet, up from 19.5% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 21.12% in Q1 2026 and bottomed at 1.45% in Q1 2023.
- A 5-year average of 10.38% and a median of 11.47% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 655 bps — and 2024, when it soared 1002 bps.
- Insulet's Return on Capital Employed stood at 2.04% in 2022, then surged by 420 bps to 10.6% in 2023, then gained by 15 bps to 12.21% in 2024, then jumped by 60 bps to 19.5% in 2025, then rose by 8 bps to 21.12% in 2026.
- Business Quant data shows PODD's Return on Capital Employed at 21.12% in Q1 2026, 19.5% in Q4 2025, and 16.79% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.52 Bn | 175.22 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 128.96 Bn | 126.09 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 107.99 Bn | 98.77 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 67.76 Bn | 66.31 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 48.09 Bn | 44.41 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 24.24% |
| 7 | GE HealthCare Technologies | 27.89 Bn | 25.61 Bn | 1.98 Bn | 9.30% |
| 8 | Smith & Nephew | 27.02 Bn | 26.45 Bn | - | - |
| 9 | Koninklijke Philips | 23.98 Bn | 20.86 Bn | 2.07 Bn | 8.38% |
| 10 | Insulet | 11.56 Bn | 11.07 Bn | 529.10 Mn | 21.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.12% |
| Dec 31, 2025 | 19.50% |
| Sep 30, 2025 | 16.79% |
| Jun 30, 2025 | 16.40% |
| Mar 31, 2025 | 12.25% |
| Dec 31, 2024 | 12.21% |
| Sep 30, 2024 | 12.50% |
| Jun 30, 2024 | 12.03% |
| Mar 31, 2024 | 11.47% |
| Dec 31, 2023 | 10.60% |
| Sep 30, 2023 | 6.94% |
| Jun 30, 2023 | 4.46% |
| Mar 31, 2023 | 1.45% |
| Dec 31, 2022 | 2.04% |
| Sep 30, 2022 | 3.53% |
| Jun 30, 2022 | 5.22% |
| Mar 31, 2022 | 8.00% |
| Dec 31, 2021 | 7.02% |
| Sep 30, 2021 | 3.98% |
| Jun 30, 2021 | 3.54% |